Pure Global
NCT06309030

Clinical Study on the Deep Remission of Rheumatoid Arthritis With Kidney Deficiency and Excessive Cold Syndrome by Bushen Quhan Zhiwang Decoction

Liu Longxiao·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Rheumatoid Arthritis
Drug/Device/Intervention
Bushen quhan zhiwang decoction
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Liu Longxiao
Funder
China-Japan Friendship Hospital
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Aug 01, 2026
Enrollment
72 participants
Primary outcome

disease activity score derivative for 28 joints (DAS28)

Summary

The investigators conduct this randomized controlled clinical trial to evaluate the efficacy
 and safety of the Bushen Quhan Zhiwang decoction in patients with RA with kidney deficiency
 and excessive cold syndrome who have not achieved deep remission and remained at a low level
 of disease activity despite the use of conventional synthetic disease-modifying antirheumatic
 drugs.

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06309030
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06309030 through Pure Global AI's free database. This phase not specified trial is sponsored by Liu Longxiao and is currently Not yet recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.